
Psilocybin, the active ingredient in “magic” mushrooms, is getting renewed interest as a potential treatment for various health conditions. Now, a new research review argues that migraines should be added to that list. Psilocybin mushrooms have long been used recreationally as hallucinogens — meaning they alter users’ perceptions of their surroundings. That can lead to euphoria on one end of the scale, or — if things go badly — anxiety, panic or dangerous hallucinations. Medical research into psychedelics like psilocybin and LSD began in the 1950s, and then famously ended after a surge in recreational use by the 1960s “counterculture.” But recent years have seen a new interest in the drugs as medical therapy. Researchers at institutions such as Johns Hopkins University, New York University and the University of California are studying psilocybin as a treatment for conditions like depression, addiction and eating disorders. While most of the research is focused on psychiatric conditions, psilocybin has also shown hints of promise against cluster headaches and migraines. In the new review, published recently in the journal Current Pain and Headache Reports, Dr. Emmanuelle Schindler, an assistant professor of neurology at Yale School of Medicine, describes the research done so far. That includes her own 2021 pilot trial, where Schindler and her colleagues tested the effects of psilocybin — given under medical supervision — in 10 patients… read on > read on >